<?xml version='1.0' encoding='utf-8'?>
<document id="31933482"><sentence text="Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives." /><sentence text="Cobicistat (COBI), a CYP3A inhibitor, is a pharmacokinetic enhancer that increases exposures of the HIV protease inhibitors (PIs) atazanavir (ATV) and darunavir (DRV)"><entity charOffset="130-140" id="DDI-PubMed.31933482.s2.e0" text="atazanavir" /><entity charOffset="151-160" id="DDI-PubMed.31933482.s2.e1" text="darunavir" /><entity charOffset="162-165" id="DDI-PubMed.31933482.s2.e2" text="DRV" /><pair ddi="false" e1="DDI-PubMed.31933482.s2.e0" e2="DDI-PubMed.31933482.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s2.e0" e2="DDI-PubMed.31933482.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s2.e0" e2="DDI-PubMed.31933482.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s2.e1" e2="DDI-PubMed.31933482.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s2.e1" e2="DDI-PubMed.31933482.s2.e2" /></sentence><sentence text=" The potential drug interaction between COBI-boosted PIs and hormonal contraceptives, which are substrates of intestinal efflux transporters and extensively metabolized by CYP enzymes, glucuronidation and sulfation, was evaluated" /><sentence text="" /><sentence text="This was a Phase I, open-label, two cohort (n=18/cohort), fixed-sequence study in healthy females that evaluated the drug-drug interaction (DDI) between multiple-dose ATV+COBI or DRV+COBI and single-dose drospirenone/ethinyl estradiol (EE)"><entity charOffset="204-216" id="DDI-PubMed.31933482.s5.e0" text="drospirenone" /><entity charOffset="217-234" id="DDI-PubMed.31933482.s5.e1" text="ethinyl estradiol" /><entity charOffset="236-238" id="DDI-PubMed.31933482.s5.e2" text="EE" /><entity charOffset="179-180" id="DDI-PubMed.31933482.s5.e3" text="DRV" /><pair ddi="false" e1="DDI-PubMed.31933482.s5.e3" e2="DDI-PubMed.31933482.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s5.e3" e2="DDI-PubMed.31933482.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s5.e3" e2="DDI-PubMed.31933482.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s5.e3" e2="DDI-PubMed.31933482.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s5.e0" e2="DDI-PubMed.31933482.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s5.e0" e2="DDI-PubMed.31933482.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s5.e0" e2="DDI-PubMed.31933482.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s5.e1" e2="DDI-PubMed.31933482.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s5.e1" e2="DDI-PubMed.31933482.s5.e2" /></sentence><sentence text=" DDIs were evaluated using 90% confidence intervals of the geometric least-squares mean ratios of the test (drospirenone/EE+boosted PI) versus reference (drospirenone/EE) using lack of DDI boundaries of 70-143%"><entity charOffset="108-120" id="DDI-PubMed.31933482.s6.e0" text="drospirenone" /><entity charOffset="154-166" id="DDI-PubMed.31933482.s6.e1" text="drospirenone" /><entity charOffset="121-132" id="DDI-PubMed.31933482.s6.e2" text="EE" /><entity charOffset="167-178" id="DDI-PubMed.31933482.s6.e3" text="EE" /><pair ddi="false" e1="DDI-PubMed.31933482.s6.e0" e2="DDI-PubMed.31933482.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s6.e0" e2="DDI-PubMed.31933482.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s6.e0" e2="DDI-PubMed.31933482.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s6.e0" e2="DDI-PubMed.31933482.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s6.e2" e2="DDI-PubMed.31933482.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s6.e2" e2="DDI-PubMed.31933482.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s6.e2" e2="DDI-PubMed.31933482.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s6.e1" e2="DDI-PubMed.31933482.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s6.e1" e2="DDI-PubMed.31933482.s6.e3" /></sentence><sentence text=" Safety was assessed throughout the study" /><sentence text="" /><sentence text="29/36 participants completed the study" /><sentence text=" Relative to drospirenone/EE alone, drospirenone area under the plasma concentration versus time curve extrapolated to infinity (AUCinf) was 1"><entity charOffset="13-25" id="DDI-PubMed.31933482.s10.e0" text="drospirenone" /><entity charOffset="36-48" id="DDI-PubMed.31933482.s10.e1" text="drospirenone" /><entity charOffset="26-37" id="DDI-PubMed.31933482.s10.e2" text="EE" /><pair ddi="false" e1="DDI-PubMed.31933482.s10.e0" e2="DDI-PubMed.31933482.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s10.e0" e2="DDI-PubMed.31933482.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s10.e0" e2="DDI-PubMed.31933482.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s10.e2" e2="DDI-PubMed.31933482.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s10.e2" e2="DDI-PubMed.31933482.s10.e1" /></sentence><sentence text="6-fold and 2" /><sentence text="3-fold higher, and maximum observed plasma concentration (Cmax) was unaltered, upon coadministration with DRV+COBI and ATV+COBI, respectively"><entity charOffset="106-114" id="DDI-PubMed.31933482.s12.e0" text="DRV+COBI" /><entity charOffset="119-127" id="DDI-PubMed.31933482.s12.e1" text="ATV+COBI" /><pair ddi="false" e1="DDI-PubMed.31933482.s12.e0" e2="DDI-PubMed.31933482.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s12.e0" e2="DDI-PubMed.31933482.s12.e1" /></sentence><sentence text=" EE AUCinf decreased 30% with drospirenone/EE + DRV+COBI and was unchanged with ATV+COBI + drospirenone/EE, relative to drospirenone/EE alone"><entity charOffset="30-42" id="DDI-PubMed.31933482.s13.e0" text="drospirenone" /><entity charOffset="43-56" id="DDI-PubMed.31933482.s13.e1" text="EE + DRV+COBI" /><entity charOffset="80-103" id="DDI-PubMed.31933482.s13.e2" text="ATV+COBI + drospirenone" /><entity charOffset="120-132" id="DDI-PubMed.31933482.s13.e3" text="drospirenone" /><entity charOffset="48-59" id="DDI-PubMed.31933482.s13.e4" text="DRV" /><entity charOffset="1-12" id="DDI-PubMed.31933482.s13.e5" text="EE" /><entity charOffset="104-115" id="DDI-PubMed.31933482.s13.e6" text="EE" /><entity charOffset="133-144" id="DDI-PubMed.31933482.s13.e7" text="EE" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e5" e2="DDI-PubMed.31933482.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e5" e2="DDI-PubMed.31933482.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e5" e2="DDI-PubMed.31933482.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e5" e2="DDI-PubMed.31933482.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e5" e2="DDI-PubMed.31933482.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e5" e2="DDI-PubMed.31933482.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e5" e2="DDI-PubMed.31933482.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e5" e2="DDI-PubMed.31933482.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e0" e2="DDI-PubMed.31933482.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e0" e2="DDI-PubMed.31933482.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e0" e2="DDI-PubMed.31933482.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e0" e2="DDI-PubMed.31933482.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e0" e2="DDI-PubMed.31933482.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e0" e2="DDI-PubMed.31933482.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e0" e2="DDI-PubMed.31933482.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e1" e2="DDI-PubMed.31933482.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e1" e2="DDI-PubMed.31933482.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e1" e2="DDI-PubMed.31933482.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e1" e2="DDI-PubMed.31933482.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e1" e2="DDI-PubMed.31933482.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e1" e2="DDI-PubMed.31933482.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e4" e2="DDI-PubMed.31933482.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e4" e2="DDI-PubMed.31933482.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e4" e2="DDI-PubMed.31933482.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e4" e2="DDI-PubMed.31933482.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e4" e2="DDI-PubMed.31933482.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e2" e2="DDI-PubMed.31933482.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e2" e2="DDI-PubMed.31933482.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e2" e2="DDI-PubMed.31933482.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e2" e2="DDI-PubMed.31933482.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e6" e2="DDI-PubMed.31933482.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e6" e2="DDI-PubMed.31933482.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e6" e2="DDI-PubMed.31933482.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e3" e2="DDI-PubMed.31933482.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s13.e3" e2="DDI-PubMed.31933482.s13.e7" /></sentence><sentence text=" Study treatments were generally well tolerated" /><sentence text=" The majority of adverse events were mild and consistent with known safety profiles of the compounds" /><sentence text="" /><sentence text="Consistent with COBI-mediated CYP3A inhibition, drospirenone exposure increased following coadministration with COBI-containing regimens, with a greater increase with ATV+COBI"><entity charOffset="48-60" id="DDI-PubMed.31933482.s17.e0" text="drospirenone" /><entity charOffset="112-116" id="DDI-PubMed.31933482.s17.e1" text="COBI" /><entity charOffset="16-19" id="DDI-PubMed.31933482.s17.e2" text="COBI" /><entity charOffset="171-174" id="DDI-PubMed.31933482.s17.e3" text="COBI" /><pair ddi="false" e1="DDI-PubMed.31933482.s17.e2" e2="DDI-PubMed.31933482.s17.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s17.e2" e2="DDI-PubMed.31933482.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s17.e2" e2="DDI-PubMed.31933482.s17.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s17.e2" e2="DDI-PubMed.31933482.s17.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s17.e0" e2="DDI-PubMed.31933482.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s17.e0" e2="DDI-PubMed.31933482.s17.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s17.e0" e2="DDI-PubMed.31933482.s17.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s17.e1" e2="DDI-PubMed.31933482.s17.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s17.e1" e2="DDI-PubMed.31933482.s17.e3" /></sentence><sentence text=" Thus, clinical monitoring for drospirenone-associated hyperkalaemia is recommended with DRV+COBI and ATV+COBI should not be used with drospirenone"><entity charOffset="31-43" id="DDI-PubMed.31933482.s18.e0" text="drospirenone" /><entity charOffset="89-97" id="DDI-PubMed.31933482.s18.e1" text="DRV+COBI" /><entity charOffset="135-147" id="DDI-PubMed.31933482.s18.e2" text="drospirenone" /><entity charOffset="93-104" id="DDI-PubMed.31933482.s18.e3" text="COBI" /><entity charOffset="106-117" id="DDI-PubMed.31933482.s18.e4" text="COBI" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e0" e2="DDI-PubMed.31933482.s18.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e0" e2="DDI-PubMed.31933482.s18.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e0" e2="DDI-PubMed.31933482.s18.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e0" e2="DDI-PubMed.31933482.s18.e4" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e0" e2="DDI-PubMed.31933482.s18.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e1" e2="DDI-PubMed.31933482.s18.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e1" e2="DDI-PubMed.31933482.s18.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e1" e2="DDI-PubMed.31933482.s18.e4" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e1" e2="DDI-PubMed.31933482.s18.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e3" e2="DDI-PubMed.31933482.s18.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e3" e2="DDI-PubMed.31933482.s18.e4" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e3" e2="DDI-PubMed.31933482.s18.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e4" e2="DDI-PubMed.31933482.s18.e4" /><pair ddi="false" e1="DDI-PubMed.31933482.s18.e4" e2="DDI-PubMed.31933482.s18.e2" /></sentence><sentence text=" Lower EE exposure with DRV+COBI may be attributed to inductive effects of DRV on CYP enzymes and/or intestinal efflux transporters (that is, P-gp) involved in EE disposition"><entity charOffset="24-32" id="DDI-PubMed.31933482.s19.e0" text="DRV+COBI" /><entity charOffset="75-82" id="DDI-PubMed.31933482.s19.e1" text="DRV" /><entity charOffset="7-14" id="DDI-PubMed.31933482.s19.e2" text="EE" /><entity charOffset="160-167" id="DDI-PubMed.31933482.s19.e3" text="EE" /><entity charOffset="28-35" id="DDI-PubMed.31933482.s19.e4" text="COBI" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e2" e2="DDI-PubMed.31933482.s19.e2" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e2" e2="DDI-PubMed.31933482.s19.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e2" e2="DDI-PubMed.31933482.s19.e4" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e2" e2="DDI-PubMed.31933482.s19.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e2" e2="DDI-PubMed.31933482.s19.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e0" e2="DDI-PubMed.31933482.s19.e0" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e0" e2="DDI-PubMed.31933482.s19.e4" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e0" e2="DDI-PubMed.31933482.s19.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e0" e2="DDI-PubMed.31933482.s19.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e4" e2="DDI-PubMed.31933482.s19.e4" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e4" e2="DDI-PubMed.31933482.s19.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e4" e2="DDI-PubMed.31933482.s19.e3" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e1" e2="DDI-PubMed.31933482.s19.e1" /><pair ddi="false" e1="DDI-PubMed.31933482.s19.e1" e2="DDI-PubMed.31933482.s19.e3" /></sentence><sentence text="" /></document>